GW Pharmaceuticals to Present at Upcoming Investor Conferences

- Morgan Stanley 15^th Annual Global Healthcare Conference on 13 September -
            - Leerink Partners Rare Disease & Immuno-Oncology Roundtable Series on 27 September -

LONDON, Sept. 05, 2017 -- GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that GW executive management will be presenting at the Morgan Stanley 15^th Annual Global Healthcare Conference on Wednesday, 13 September 2017 at 11:05 a.m. EDT at the Grand Hyatt Hotel in New York City and the Leerink Partners Rare Disease & Immuno-Oncology Roundtable Series on Wednesday, 27 September 2017 at 2:30 p.m. EDT at the Lotte New York Palace in New York City.

A live audio webcast of the presentations will be available through GW’s corporate website at www.gwpharm.com on the Investors section under Events & Presentations. A replay will be available soon after the live presentation.

About GW Pharmaceuticals plc

Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW is advancing an orphan drug program in the field of childhood epilepsy with a focus on Epidiolex (cannabidiol), for which GW has commenced a rolling NDA submission with the FDA for the treatment of Dravet syndrome and Lennox-Gastaut syndrome. The Company continues to evaluate Epidiolex in additional epilepsy conditions and currently has ongoing Phase 3 clinical trials in Tuberous Sclerosis Complex and Infantile Spasms. GW commercialized the world’s first plant-derived cannabinoid prescription drug, Sativex^®, which is approved for the treatment of spasticity due to multiple sclerosis in 30 countries outside the United States. The Company has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 trials for glioma, schizophrenia and epilepsy. For further information, please visit www.gwpharm.com.

Enquiries:

GW Pharmaceuticals plc
Stephen Schultz, VP Investor Relations (U.S.) 917 280 2424 / 401 500 6570